Completed pilot clinical trials on the use of anakinra in patients with reperfused STEMI undergoing primary percutaneous coronary intervention showed that IL-1 blockade was safe and reduced C-reactive protein (CRP) levels at 72 h and the rate of new-onset cardiac failure after STEMI infarction [88,89,90]. The gene discussed is IL1B; the disease is heart failure.